Kornimate/medical-research-clean huggingface dataset:
study of xl999 in patients with acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia; AML

Summary: this clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of xl999 when given weekly to patients with relapsed or newly-diagnosed aml. xl999 is a small molecule inhibitor against flk1/kinase insert domain receptor (kdr), pdgfr, c-kit, flt3 and src. c-kit and flt3 are receptors commonly expressed on aml blasts.


Eligibility criteria:
inclusion criteria: * diagnosis of acute myeloid leukemia (except aml fab-m3 or acute promyelocytic leukemia \[apl\]) based on the world health organization (who) classification of ≥ 20% blasts in the bone marrow or peripheral blood at initial diagnosis (prior to start of standard chemotherapy) * ecog performance status of 0 or 1 * subjects with newly-diagnosed aml or subjects with relapsed aml after at least 2 chemotherapy regimens. * adequate liver and renal function * signed informed consent exclusion criteria: * anticancer therapy including chemotherapeutic, biologic, or investigative agents within 30 days of xl999 treatment * hematopoietic stem cell transplantation within the previous 6 weeks * immunosuppressive therapy (eg, cyclosporine, steroids, tacrolimus) for graft-versus-host disease (gvhd) within 30 days prior to the start of xl999 * the subject has not recovered to grade ≤ 1 or to within 10% of baseline from adverse events due to investigational or chemotherapeutic drugs or stem cell transplantation which were administered \> 4 weeks prior to study enrollment * uncontrolled and/or concomitant illness * pregnant or breastfeeding females * known hiv

Keywords: acute myeloid leukemia aml
penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable hnscc

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: this study aims to observe and explore the efficacy and safety of penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: * patients voluntarily joined the study, signed the informed consent, and had good compliance; * patients with 18 years to 75 years(at the time of signing the informed consent); eastern cooperative oncology group performance status (ecog-ps) score: 0-1; * patients with untreated head and neck squamous cell carcinoma who were pathologically confirmed and determined to be suitable for surgical treatment were classified as stage iii, iva according to ajcc (8th edition), including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers * female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; male patients should agree to use contraception during the study period and for six months after the end of the study. exclusion criteria: * patients who have previously used pd-1/pd-l1/ctla-4 antibody therapy; * patients who require systemic treatment with corticosteroids (\> 10mg daily prednisone equivalent) or other immunosuppressive drugs within 14 days prior to administration or during treatmentin the absence of active autoimmune disease, inhaled or topical steroids and adrenocortical hormone at doses \>10mg/ day equivalent to prednisone and adrenocortical hormone replacement at therapeutic doses not exceeding 10mg/ day prednisone are permitted; * a history of any active immune or autoimmune disease, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; * active or uncontrolled severe infection within 4 weeks prior to enrollment (ctcae grade 2 infection); * abnormal function of major organs * patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.
effect of laughter therapy on perceived stress and quality of life

Conditions: Laughter Therapy

Summary: breast cancer is the most common type of cancer seen in women worldwide and ranks first. chemotherapy is one of the commonly used methods of treatment in breast cancer. physiological and psychological symptoms that occur due to chemotherapy treatment affect women negatively and reduce their quality of life. for this reason, there is a need for an intervention that could decrease psychological symptoms such as stress and improve quality of life in women with breast cancer. in the literature, it is stated that laughter therapy which is one of the non-pharmacological methods, can be an effective nursing intervention to decrease stress and improve the quality of life in women with breast cancer.

this an assessor-blinded, parallel group randomized controlled trial aimed that investigating the effect of laughter therapy on perceived stress and quality of life in women with breast cancer.this trial was conducted in the chemotherapy outpatient clinic of training and research hospital located in turkey. all patients were women with breast cancer who received a once-weekly paclitaxel regimen.

Eligibility criteria:
inclusion criteria: * 18 years and older women, * stages ii or iii breast cancer * receiving pacitaxel chemotherapy regimen per a week exclusion criteria: * using any complementary and alternative (cam) treatment method during practice * having psychological diseases

Keywords: perceived stress quality of life laughter therapy breast cancer
evolution of neoadjuvant treatment in 'triple-negative' or 'her-2-positive' breast cancer diagnosed in the early phase

Conditions: Breast Cancer

Summary: the primary objective of this study is to describe the percentage of patients with her2-positive and triple negative tumour underwent neoadjuvant treatment in clinical practice during the past 5 years out of total number of patients who underwent neoadjuvant treatment, regardless molecular subtypes. secondary objectives the secondary objectives which are limited to molecular subtypes of study interest, her2-positive and triple negative tumours, are follow reported: * to perform a descriptive analysis on neoadjuvant treatment choice according to molecular subtype and initial staging; * to perform a descriptive analysis on clinical and tumour pathological characteristics according to molecular subtypes and initial staging; * to perform radiological response descriptive analysis achieved with neoadjuvant therapy according to treatment and instrumental examination type (for example: breast mri, breast ultrasound or mammography); * to perform a descriptive analysis of surgical procedures for both, the breast and the axilla, according to radiological tumour response, initial staging and molecular subtypes; * to perform a descriptive analysis on therapies performed in adjuvant setting according to neoadjuvant treatment type, initial staging and molecular subtypes; * to describe and to analyse the eligibility criteria evolution in neoadjuvant treatment setting during the last 5 years; * to perform a descriptive analysis on pathological complete response (cpr) according to neoadjuvant treatment, molecular subtypes and initial staging; * to evaluate disease-free survival (dfs) according to pcr and molecular subtypes; * to evaluate overall survival (os) according to pcr and molecular subtypes.


Eligibility criteria:
inclusion criteria: * for primary endpoint assessment we calculated the percentage of her2 positive and triple negative patients who underwent neoadjuvant treatment in the past 5 years in each site. for this aim all patients with early breast cancer diagnosis who underwent neoadjuvant treatment during the study time, ranging from 01/01/2016 to 01/01/2021, will be included if they had: * histological diagnosis of infiltrating breast cancer performed by breast and/or axillary nodes biopsy; * age ≥ 18 years at the time of disease onset; * absence of secondary lesions, i.e. initial disease stage i, ii or iii; * known status of er, pgr, her-2 and ki67. exclusion criteria: * documented distant disease at onset diagnosis or within 3 months from breast surgery; * prior neoadjuvant hormonal treatment exposure; * prior diagnosis of primary breast cancer or second primitive tumour starting from different organ
study on immune status of patients with covid-19

Conditions: COVID-19; Immunity; Life Quality

Summary: this study is a prospective cohort study aimed to clarify the continuous immune state changes of patients with covid-19. investigators include the patients admitted to the hospital within one week after the onset of covid-19. 10ml of patients' blood was collected day 1, day 7, day 14 , and day 20 after the patients admitted to the hospital. the blood inflammatory factors, immune related molecules, and immune cells were detected to determine the changes of patients' immune status. the impact of immune status changes on prognosis and quality of life in later follow-up period was evaluated by various questionnaires and evaluation scales.

after sars-cov-2 infection, the patient's immune system is overactivated. while the immune cells release a large number of proinflammatory factors, anti-inflammatory response starts at the same time. anti-inflammatory factors such as interleukin 4 (il-4), interleukin 10 (il-10) and interleukin 37 (il-37) will be compensated to resist the release of proinflammatory factors and prevent the further development of systemic inflammatory response. however, when the anti-inflammatory factor is excessively released, it will cause compensatory response syndrome, leading to immunosuppression. whether the level of anti-inflammatory factors continues to rise, and whether it will lead to the persistence of later immunosuppression is unknown. therefore, this study intends to recruit patients infected with novel coronavirus to enter the hospital within one week of onset, and collect 10ml of patients' blood on the first, seventh, fourteenth and twentieth day after the patients feel the hospital feeling, respectively, to detect the blood inflammatory factors, immune related molecules and immune cells, and determine the changes of patients' immune status. the patients were followed up for 2 and 6 months after arriving at the hospital to conduct self-reported symptom questionnaire, health related quality of life (hrqol) questionnaire, hospital anxiety and depression scale (hads), and other questionnaires and scales to assess the impact of changes in the patient's immunological status on the prognosis and later quality of life.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed as novel coronavirus infection by pcr or antigen rapid detection for the first time 2. patients hospitalized within one week after the occurrence of clinical symptoms related to novel coronavirus infection (fever, cough, shortness of breath or dyspnea, fatigue, headache, muscle or body pain, sore throat, nasal congestion or runny nose, chills, nausea, vomiting, diarrhea, mental state changes) 3. age over 18, gender unlimited exclusion criteria: 1. patients with immunosuppression, including hiv infection, hematopoietic stem cell transplantation and high-dose immunosuppressant therapy 2. patients with severe autoimmune diseases 3. patients receiving chemotherapy or cancer treatment 4. pregnancy or breastfeeding
effect of root canal treatment (versus no treatment) for patients with tooth infections and toothaches

Conditions: Postoperative Pain

Summary: the purpose of this study is to evaluate patients with emergency pain and a sore (infected) tooth to determine if immediate root canal therapy is better at reducing pain, when compared to initial treatment with antibiotic and pain medication followed by root canal therapy. each participant will be randomly assigned a number, which will determine if they will receive initial endodontic treatment that day or at a later date. each participant will receive an anesthetic injection, pain medication and a prescription for an antibiotic. they will be asked to keep a diary to record their pain level after the injection and their pain levels and the amount and type of pain medication taken each day for the next 5 days. participants who did not receive root canal therapy at the initial appointment will receive it after the 5 day postoperative period. the pain levels and medication use will be compared between the treatment and nontreatment groups.


Eligibility criteria:
inclusion criteria: * 18 years or older * in good health (asa classification i or ii) * able to give informed consent * infected tooth with toothache (symptomatic tooth with pulpal necrosis) exclusion criteria: * allergy to ibuprofen, acetaminophen or codeine * history of significant medical problems (asa classification iii or greater) * angioedema or bronchospastic reactivity to aspirin or other nsaids * pregnant or lactating * inability to give informed consent

Keywords: postoperative pain root canal treatment
together overcoming diabetes - great plains

Conditions: Diabetes

Summary: the goal of this research is to evaluate a scientifically rigorous diabetes intervention, together overcoming diabetes (tod), that has been tailored to address the unique underlying risk and protective factors and social determinants of diabetes among american indian/alaska native (ai/an) populations.


Eligibility criteria:
inclusion criteria - adult index participants: * 18 years and older * self-identifies as american indian or alaska native * rapid city-based participants who reside within 1 hour transportation range of the oyate health center * verification from a health provider to confirm type 2 diabetes diagnosis by laboratory test. * caregiver to a 10- to 25-year-old in their home at the time of screening. * willing to complete all implementation and follow-up assessments. * willing to be randomized for the intervention. exclusion criteria - adult index participants: * inability to participate in full intervention or evaluation (e.g., planned move, residential treatment, etc.) * willing to serve as 'support person' for the adult participant. * has a circumstance that might impact successful participation based on provider judgment considering instances where diabetes control can become more difficult with advanced disease or special conditions including: pregnant, nursing, or planning to become pregnant, end-stage renal disease on dialysis, diabetes due to secondary causes such as cushing's or cystic fibrosis, or any condition that may inhibit participation inclusion criteria - youth support participants: * between 10 years and 25 years old * self-identifies as american indian or alaska native. * willing to serve as 'support person' for the adult participant. * willing to complete all implementation and follow-up assessments. * willing to be randomized for the intervention. exclusion criteria - youth support participants: * cognitively or visually impaired * youth in foster care (due to potential mobility of foster youth).
psychiatric disorders related to diabetes mellitus type 1 among children in egypt

Conditions: Diabetes Mellitus Type 1; Adolescents; Psychiatric Disorders

Summary: type 1 diabetes is the most common endocrine disorder in children and adolescents. it is characterised by a deficiency in insulin synthesis and requires daily insulin injections to manage glucose levels. therefore, there are numerous medical approaches to its therapy, such as levels of glycosylated haemoglobin (hba1c) as a marker of glycaemic control during the last 3 months and monitoring of blood glucose levels, influencing the mental health and the quality of life of the patient and family. hens, the importance of the psychological adjustment to children and adolescents with type 1 diabetes besides insulin injection, adequate diet and regular exercise rises, in order to maintain stable psychological status and functional mental health, and prevent psychological disorders such as anxiety, depression and sleep disorders. approaching the comorbidity in these children and adolescents starts with the diagnosis and with the health changes in all aspects.


Eligibility criteria:
inclusion criteria: 1. both boys and girls aged 6-12 years. 2. willing of the parents or the caregivers to participate in the study. 3. duration of type 1 dm of at least 1 year. exclusion criteria: 1. children with intelligence quotient below 70. 2. children with history of substance use. 3. children with another medical or neurological conditions.
thoracoabdominal aortic aneurysms

Conditions: Thoracoabdominal Aortic Aneurysm

Summary: evaluation of the effectiveness of the different modalities for treatment of thoracoabdominal aortic aneurysms. fevar and bevar devices are widely used now due to its feasability and wide range of use . we aim to evaluate the effectiveness of these new devices in the management of taaa


Eligibility criteria:
inclusion criteria: * all adult consecutive patients presenting with taaa larger than 5.5 cm exclusion criteria: * active infection asymptomatic patients with small aneurysms allergy to contrast agents
phase iii trial comparing, neoadjuvant chemotherapy followed by standard radiotherapy versus the same neoadjuvant chemotherapy followed by standard radiotherapy associated with daily hydroxyurea in the treatment of locally advanced undifferentiated carcinoma nasopharyngeal type.

Conditions: LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT

Summary: multicentric international randomized phase iii trial comparing, neoadjuvant chemotherapy (bec regimen) followed by standard radiotherapy (70 gy / 7 weeks) versus the same neoadjuvant chemotherapy followed by standard radiotherapy associated with daily hydroxyurea in the treatment of locally advanced undifferentiated carcinoma nasopharyngeal type (ucnt).


Eligibility criteria:
inclusion criteria: * of either sex * aged \*15 and \* 70 years * never previously treated with radiotherapy, chemotherapy or surgery for malignant disease (except neck adenectomy/diagnosis) * with awho performance status \* 2. * amenable to regular follow-up * capable of receiving chemotherapy and radiotherapy : in particular, with no contraindications to the use of anthracyclines, bleomycin or cisplatinum. * with informed consent at entry time, in writing or witnessed oral informed consent, in accordance with local legislation requirements. * laboratory requirement : \*baseline hematologic status : neutrophil count \* 2000 /mm3 platelet count \* 150,000 /mm3 hemoglobin \* 10 g / dl exclusion criteria: * histologic types other than type ii - iii of the who classification * t1 - t2 n0 - n1 or patients with metastatic * aged \ 70. * patients in whom chemotherapy is contraindicated: history of myocardial infarction over the last 6 months before inclusion, or clinically present cardiac pathology. * who performance status \>2 * history of prior malignancies (other than non melanoma skin cancer or excised cervical carcinoma in situ). * uncontrolled infection, * patients refusing participation. * patients who, for social, familial or geographic reasons are unlikely to comply with a long term follow-up.
long-term outcome of end-stage renal disease patients treated with hig-efficiency hemodiafiltration

Conditions: End-stage Renal Disease

Summary: a retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in king chulalongkorn memorial hospital between 2001-2013 to determine the survival rate as well as other long-term outcome.

growing evidences suggested the superiority of high-efficiency hemodiafiltration (hdf) which could provide both diffusion and convection in a single therapy compared with the conventional hemodialysis. however, the long-term, upto 10 years, outcome still limited. this retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in a single-center, king chulalongkorn memorial hospital, between 2001-2013 to determine the survival rate as well as other long-term outcome

Eligibility criteria:
inclusion criteria: * aged 18 years or more * be diagnosed end-stage renal disease for more than one year * have been regularly received long-term hemodiafiltration for more than 6 months. exclusion criteria: * patients who received hemodiafiltration less than 6 months

Keywords: survival hemodiafiltration end-stage renal disease hemodialysis
study to evaluate arthroplasty specimens for osteoarthritis of the knee and hip

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: the objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with osteoarthritis (oa) who have been treated with fasinumab, compared with those treated with placebo or non-steroidal anti-inflammatory drugs (nsaids).


Eligibility criteria:
key inclusion criteria: * previously randomized to r475-pn-1523 (nct02683239), r475-oa-1611 (nct03161093), or r475-oa-1688 (nct03304379) and received at least 1 dose of study drug * notified the site that they are planning a knee or hip arthroplasty during the parent study between randomization and 24 weeks after the last dose of subcutaneous (sc) study drug * patient's surgeon/pathologist is willing to coordinate with the site regarding preparation, storage, and shipping of joint tissue samples collected during arthroplasty surgery exclusion criteria: * none note: other protocol inclusion criteria apply
asthmaxcel emergency department study

Conditions: Asthma; Asthma Attack

Summary: this protocol focuses on phase 1 of a planned two-phase research project. phase 1 aims to test and adapt a prototype asthmaxceled application for the ed. phase 2 will be an rct to test the efficacy of a refined asthmaxceled app after being modified based on the results of phase 1.

the original asthmaxcel app was developed by dr. jariwala, which delivers asthma education and promotes patients' adherence to the national asthma guidelines. the app was developed in accordance with montefiore medical center's regulatory/compliance (determined by the montefiore legal department and einstein-montefiore office of biotechnology) and security (determined by montefiore it) policies. over the last several years the app has been iteratively improved based on patient feedback and has been shown to improve asthma knowledge, asthma control, and asthma-related quality of life among asthma clinic patients. this version of the app has been tailored to the ed, requiring less physician directed education and focusing on common triggers and symptom management. research associates will ask each patient to download the asthmaxceled app and ra's instruct them on use of the application. ra's will also show every patient a video using the asthmaxceled mobile application in which the investigators demonstrate correct use of an inhaler and discuss asthma triggers.

Eligibility criteria:
inclusion criteria: * english speakers * at least 18+ years old with * physician-diagnosed asthma. exclusion criteria: * severe cognitive or psychiatric conditions precluding capacity to provide informed consent, * inability to speak english, * lacking the technology to access the app.